ChromaDex appoints James Lee as Interim CFO after Brianna Gerber resignation

Niagen Bioscience, Inc.

Brianna Gerber resigned as CFO and Principal Accounting Officer effective July 12, 2024.
James Lee, Controller since 2009, appointed Interim CFO and Interim Principal Accounting Officer effective July 13, 2024.
Gerber will consult on financial and accounting matters through August 12, 2024 under prior agreement.
Lee holds B.A. in Architecture from UC Berkeley and MBA from UIUC; previously accounting manager at Samsung.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

James Lee

Interim Chief Financial Officer and Interim Principal Accounting Officer

NAGE · Niagen Bioscience, Inc.

Effective: 2024-07-13
Filed: July 16, 2024, 7:59 PM ET

On July 16, 2024, the Board of Directors (the “Board”) of ChromaDex Corporation (the “Company” or “ChromaDex”) appointed James Lee, the Company’s current Controller, as the Company’s Interim Chief Financial Officer and Interim Principal Accounting Officer, effective as of July 13, 2024.

Departed

Brianna Gerber

Chief Financial Officer and Principal Accounting Officer

NAGE · Niagen Bioscience, Inc.

Effective: 2024-07-12
Successor: James Lee
Filed: July 16, 2024, 7:59 PM ET

As previously disclosed, Brianna Gerber resigned from her roles as the Company’s Chief Financial Officer and Principal Accounting Officer effective July 12, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James Lee was appointed as Interim Chief Financial Officer and Interim Principal Accounting Officer at Niagen Bioscience, Inc..

Action: appointed
Role: Interim Chief Financial Officer and Interim Principal Accounting Officer

Exact text from the filing

On July 16, 2024, the Board of Directors (the “Board”) of ChromaDex Corporation (the “Company” or “ChromaDex”) appointed James Lee, the Company’s current Controller, as the Company’s Interim Chief Financial Officer and Interim Principal Accounting Officer, effective as of July 13, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Brianna Gerber resigned as Chief Financial Officer and Principal Accounting Officer at Niagen Bioscience, Inc..

Action: resigned
Role: Chief Financial Officer and Principal Accounting Officer

Exact text from the filing

As previously disclosed, Brianna Gerber resigned from her roles as the Company’s Chief Financial Officer and Principal Accounting Officer effective July 12, 2024.

View on SEC.gov

Niagen Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-031955

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.